S&P 500   3,091.88 (+0.00%)
DOW   27,769.68 (+0.28%)
QQQ   201.21 (-0.16%)
CGC   18.44 (-4.21%)
BABA   181.95 (-2.68%)
GE   11.26 (-1.40%)
T   39.15 (-0.05%)
F   8.82 (-2.43%)
ACB   3.56 (-0.28%)
DIS   148.80 (+7.37%)
S&P 500   3,091.88 (+0.00%)
DOW   27,769.68 (+0.28%)
QQQ   201.21 (-0.16%)
CGC   18.44 (-4.21%)
BABA   181.95 (-2.68%)
GE   11.26 (-1.40%)
T   39.15 (-0.05%)
F   8.82 (-2.43%)
ACB   3.56 (-0.28%)
DIS   148.80 (+7.37%)
S&P 500   3,091.88 (+0.00%)
DOW   27,769.68 (+0.28%)
QQQ   201.21 (-0.16%)
CGC   18.44 (-4.21%)
BABA   181.95 (-2.68%)
GE   11.26 (-1.40%)
T   39.15 (-0.05%)
F   8.82 (-2.43%)
ACB   3.56 (-0.28%)
DIS   148.80 (+7.37%)
S&P 500   3,091.88 (+0.00%)
DOW   27,769.68 (+0.28%)
QQQ   201.21 (-0.16%)
CGC   18.44 (-4.21%)
BABA   181.95 (-2.68%)
GE   11.26 (-1.40%)
T   39.15 (-0.05%)
F   8.82 (-2.43%)
ACB   3.56 (-0.28%)
DIS   148.80 (+7.37%)
Log in

Ardelyx Stock Price, Forecast & Analysis (NASDAQ:ARDX)

$6.13
+0.08 (+1.32 %)
(As of 11/13/2019 03:48 PM ET)
Today's Range
$5.98
Now: $6.13
$6.21
50-Day Range
$4.26
MA: $4.91
$6.09
52-Week Range
$1.60
Now: $6.13
$6.78
Volume17,654 shs
Average Volume466,695 shs
Market Capitalization$385.63 million
P/E RatioN/A
Dividend YieldN/A
Beta1.65
Ardelyx, Inc, a specialized biopharmaceutical company, develops and sells medicines for the treatment of cardio renal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARDX
CUSIPN/A
Phone510-745-1700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.61 million
Book Value$1.86 per share

Profitability

Net Income$-91,300,000.00

Miscellaneous

Employees86
Market Cap$385.63 million
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable

Receive ARDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.


Ardelyx (NASDAQ:ARDX) Frequently Asked Questions

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

How were Ardelyx's earnings last quarter?

Ardelyx Inc (NASDAQ:ARDX) released its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.37) EPS for the quarter, hitting analysts' consensus estimates of ($0.37). The biopharmaceutical company earned $3.01 million during the quarter. View Ardelyx's Earnings History.

When is Ardelyx's next earnings date?

Ardelyx is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Ardelyx.

What price target have analysts set for ARDX?

3 analysts have issued 12 month target prices for Ardelyx's shares. Their forecasts range from $9.00 to $15.00. On average, they expect Ardelyx's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 79.4% from the stock's current price. View Analyst Price Targets for Ardelyx.

What is the consensus analysts' recommendation for Ardelyx?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ardelyx.

Has Ardelyx been receiving favorable news coverage?

Media stories about ARDX stock have been trending very negative on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ardelyx earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Ardelyx.

Are investors shorting Ardelyx?

Ardelyx saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 1,570,000 shares, an increase of 10.6% from the September 30th total of 1,420,000 shares. Based on an average trading volume of 1,100,000 shares, the short-interest ratio is currently 1.4 days. Approximately 3.4% of the company's stock are sold short. View Ardelyx's Current Options Chain.

Who are some of Ardelyx's key competitors?

What other stocks do shareholders of Ardelyx own?

Who are Ardelyx's key executives?

Ardelyx's management team includes the folowing people:
  • Mr. Michael G. Raab, Pres, CEO & Director (Age 54)
  • Mr. David Rosenbaum, Chief Devel. Officer (Age 58)
  • Mr. Mark E. Kaufmann, CFO & Treasurer (Age 51)
  • Mr. Jeffrey W. Jacobs, Sr. VP of Technical Operations (Age 56)
  • Mr. Bryan Shaw, Chief Accounting Officer, VP and Controller (Age 65)

Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Rhumbline Advisers (0.12%), Wedbush Securities Inc. (0.05%) and Tower Research Capital LLC TRC (0.03%). Company insiders that own Ardelyx stock include David P Rosenbaum, Elizabeth A Grammer, Gordon Ringold, Mark Kaufmann, Michael Raab and Scott D Sandell. View Institutional Ownership Trends for Ardelyx.

Which institutional investors are selling Ardelyx stock?

ARDX stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have sold Ardelyx company stock in the last year include David P Rosenbaum, Elizabeth A Grammer, Mark Kaufmann and Michael Raab. View Insider Buying and Selling for Ardelyx.

Which institutional investors are buying Ardelyx stock?

ARDX stock was bought by a variety of institutional investors in the last quarter, including Tower Research Capital LLC TRC and Rhumbline Advisers. View Insider Buying and Selling for Ardelyx.

How do I buy shares of Ardelyx?

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $6.13.

How big of a company is Ardelyx?

Ardelyx has a market capitalization of $385.63 million and generates $2.61 million in revenue each year. The biopharmaceutical company earns $-91,300,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Ardelyx employs 86 workers across the globe.View Additional Information About Ardelyx.

What is Ardelyx's official website?

The official website for Ardelyx is http://www.ardelyx.com/.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]


MarketBeat Community Rating for Ardelyx (NASDAQ ARDX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  374 (Vote Outperform)
Underperform Votes:  315 (Vote Underperform)
Total Votes:  689
MarketBeat's community ratings are surveys of what our community members think about Ardelyx and other stocks. Vote "Outperform" if you believe ARDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel